Bupropion treatment of attention-deficit hyperactivity disorder in adults
American Journal of PsychiatryPublished 1 August 1990
Paul H. Wender, Fred Reimherr
Citations139
SJR quartileQ1
SJR score5.27
SNIP3.68
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Results suggest that bupropion may be an alternative to stimulants in treating some adults with attention-deficit hyperactivity disorder.
Abstract
The authors treated 19 adults with attention-deficit hyperactivity disorder with an open trial of bupropion. These patients had received maintenance stimulant medication or monoamine oxidase inhibitors for an average of 3.7 years. Fourteen of the patients experienced moderate to marked benefit from bupropion; ten of these patients chose to continue bupropion rather than their former medication. These results suggest that bupropion may be an alternative to stimulants in treating some adults with attention-deficit hyperactivity disorder.
Keywords
Medicine
Archives of General PsychiatryDiagnosis and Treatment of Minimal Brain Dysfunction in Adults
344 Citations1976D. Wood
To test the hypothesis that MBD does persist into adulthood, 15 putative MBD adults were identified on the basis of current MBD-like complaints, self-description of MBD characteristics in childhood, and a parental rating of "hyperactivity" in childhood.
Archives of General PsychiatryAttention Deficit Disorder ('Minimal Brain Dysfunction') in Adults
339 Citations1981Paul H. Wender
Pemoline was demonstrably more effective than placebo in a random-assignment, parallel, double-blind trial of placebo and pemoline, a noneuphorigenic psychostimulant drug effective in children with ADD.
American Journal of PsychiatryA controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults
259 Citations1985Paul H. Wender, Fred Reimherr +2 more
Archives of Pediatrics and Adolescent MedicineMinimal Brain Dysfunction in Children.
240 Citations1971Donald Kerr Grant
This exhaustive monograph tells us how the knowledge of the basic neurophysiologic and neuropathologic mechanisms underlying these disorders is woefully meager, and how to go about the business of identifying such children and having their care.
Journal of Pharmacology and Experimental TherapeuticsBehavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo.
210 Citations1980Barrett R. Cooper, T J Hester +1 more
Results indicate that bupropion is a selective dopamine uptake inhibitor in vivo and that dopaminergic systems play an important role in its central nervous system pharmacology.
The Journal of Nervous and Mental DiseaseTHE MINIMAL BRAIN DYSFUNCTION SYNDROME IN CHILDREN
108 Citations1972Paul H. Wender
The hypothesis that the genetic subgroup of MBD is caused by a disorder of monoamine metabolism is advanced, and it is proposed that this disordered metabolism leads to certain basic psychological dysfunctions which in turn generate the observed behavioral deviations.
The Canadian Journal of PsychiatryBupropion Effects in Attention Deficit and Conduct Disorders
73 Citations1986Jovan Simeon, H. Bruce Ferguson +1 more
Children with Attention Deficit and/or Conduct Disorders were treated with bupropion, a new antidepressant, to determine its clinical, cognitive, and EEG effects and it was revealed that degree of clinical improvement was indexed by baseline EEG parameters and that there were significant bupropions effects on EEG measures.
Psychiatry ResearchAn open trial of pargyline in the treatment of attention deficit disorder, residual type
72 Citations1983Paul H. Wender, D. Wood +2 more
Clinically useful features of pargyline in the treatment of attention deficit disorder, residual type are that its duration of action is greater than 24 hours and that it has not been abused.
Psychiatry ResearchCerebrospinal fluid homovanillic acid and 5-hydroxyindoleacetic acid in adults with attention deficit disorder, residual type
47 Citations1984Frederick W. Reimherr, Paul H. Wender +2 more
Following the hypothesis that attention deficit disorder in adults and children, as well as in children, is associated with decreased central dopaminergic activity, lumbar cerebrospinal fluid monoamine metabolites were measured in a group of adults with ADD, RT and matched control subjects.
American Journal of PsychiatryAn open trial of L-tyrosine in the treatment of attention deficit disorder, residual type
46 Citations1987Frederick W. Reimherr, Paul H. Wender +2 more
An open 8-week trial of L-tyrosine in 12 adults with attention deficit disorder, residual type showed eight showed marked to moderate clinical response in 2 weeks; at 6 weeks these eight developed tolerance, suggesting that L-Tyrosine is not useful in attention deficit Disorder, residualtype.